Business Wire

1937 Alfa Romeo 8C 2900B Berlinetta Named the Most Prestigious Car in the World

8.2.2019 12:06:00 EET | Business Wire | Press release

Share

Arguably one of the most desirable cars of all time, the remarkable 1937 Alfa Romeo 8C 2900B Berlinetta today was revealed at The Peninsula Paris hotel as the winner of the fourth annual The Peninsula Classics Best of the Best Award.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190208005130/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The 1937 ALFA ROMEO 8C 2900B BERLINETTA was named winner of The Peninsula Classics Best of the Best Award. (Photo: Jana Call me J)

While eight stunning ‘Best of Show’ winners from top concours around the world competed for the accolade, the Alfa Romeo was the stand-out choice among the judges as the best car in the world. Hailing from Los Angeles, California, the car was entered into the running for the award after being named ‘Best of Show’ at the 2018 Pebble Beach Concours d’Elegance.

“The winning Alfa Romeo is a perfect example of the type of car that inspired us to create this award,” said William E. (Chip) Connor, Chairman and CEO of William E. Connor & Associates Ltd, and co-founder of The Peninsula Classics Best of the Best Award. “To provide an opportunity for car lovers to pause a moment and celebrate flawless design and engineering of this calibre is truly an honour each year.”

The Alfa Romeo is owned by David and Ginny Sydorick of Los Angeles, California. Reflecting on the car’s recent recognition, David said: “As an avid auto-collector, having two cars in the running for this year’s award was truly remarkable. It goes without saying that Ginny and I are ecstatic at the result – a proud moment for us both.”

The winning car was unveiled using a ‘shutter-effect’, whereby individual slats turned in sync to reveal the Alfa Romeo standing proudly within a bespoke-designed, up-lit box. Following the big reveal, guests at the party, including ‘Beauty and the Beast,’ ‘The Alienist,’ and ‘Girl on a Train’ star Luke Evans, were further treated to a music set from notable DJ and On-Camera Personality, Hannah Bronfman, who was joined by husband, DJ and Entrepreneur, Brendan Fallis.

An automotive jewel engineered by Ingegner Vittorio Jano, the 8C 2900 was designed to compete in sports car races, specifically the Mille Miglia, which it won outright in 1935, 1936, 1937, 1938 and 1947. In racing trim, they dominated all the major competitions, and in road trim, they were the fastest grand touring cars.

Established in 1925 in Milan, Italian coachbuilder Carrozzeria Touring had first licensed Charles Weymann's system of fabric-covered lightweight frames and then developed its own ‘Superleggera’ construction. Patented in 1936, the Superleggera system consists of a structural framework of small-diameter steel tubes that conform to an automobile body's shape and are covered by thin alloy body panels that strengthen the framework. The winning vehicle, 412020, is the first of only five known Berlinettas built on the Lungo chassis and is the car that Touring refers to as the beginning of Superleggera.

About The Peninsula Classics Best of the Best Award

Through a shared desire to celebrate the best of what defines the automotive world, The Hon. Sir Michael Kadoorie, Chairman of The Hongkong and Shanghai Hotels, Limited, launched The Peninsula Classics Best of the Best Award in 2015 with co-founders William E. (Chip) Connor, Bruce Meyer and Christian Philippsen. Each founder shares a common passion and appreciation of fine motor cars, the preservation of their heritage and immaculate restoration projects. The award, sponsored by The Peninsula Hotels, brings together eight of the concours circuits’ elite ‘Best of Show’ winners from around the globe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sanaz Marbley/Devon Zahm
JMPR Public Relations
+1 (818) 992 4353
smarbley@jmpr.com / dzahm@jmpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye